Literature DB >> 8198394

Antidepressants in long-term treatment.

S A Montgomery1.   

Abstract

One of the most important recent developments in the management of depression is the recognition of the need for long-term treatment. Treatment of an episode of depression must continue after apparent response in order to consolidate response and prevent relapse. A continuation treatment period of at least four months after response of the acute episode is required in all patients with depression. Most depression is recurrent, and prophylactic treatment with antidepressants reduces the risk of new episodes. This treatment needs to be continued over very long periods, because the risk of new episodes does not appear to diminish with time. In selecting an antidepressant for long-term treatment efficacy, safety and tolerability in the long term should be taken into account since not all antidepressants have been adequately tested, and some do not appear to be effective. The most thoroughly tested antidepressants are the tricyclic imipramine and the new selective serotonin reuptake inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198394     DOI: 10.1146/annurev.med.45.1.447

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  6 in total

Review 1.  Continuation and maintenance therapy of early-onset major depressive disorder.

Authors:  Graham J Emslie; Taryn L Mayes; Maryse Ruberu
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Sertraline. A pharmacoeconomic evaluation of its use in depression.

Authors:  R Davis; M I Wilde
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

3.  Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France.

Authors:  M Nuijten; L Hadjadjeba; C Evans; J van den Berg
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 4.  Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Authors:  R Davis; R Whittington; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

5.  Clomipramine and related structures as inhibitors of the skeletal sarcoplasmic reticulum Ca2+ pump.

Authors:  F Soler; F Plenge-Tellechea; I Fortea; F Fernandez-Belda
Journal:  J Bioenerg Biomembr       Date:  2000-04       Impact factor: 2.945

6.  Binding and competitive inhibition of amine uptake at postsynaptic neurones (transport-P) by tricyclic antidepressants.

Authors:  S Al-Damluji; I J Kopin
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.